No. 18314A, a phase IV study, entitled “Interventional, open-label effectiveness study of flexible doses of vortioxetine on depressive symptoms in patients with major depressive disorder co-morbid with generalized anxiety disorder”, and No. 18315A, a phase IV study, entitled “Interventional, open-label study of flexible doses of vortioxetine on depressive symptoms in patients with major depressive disorder and early dementia”